Patient Information Leaflet
Protamine sulfate LEO Pharma 1,400 UI anti-heparin (10mg)/ml
injectable and infusion solution
protamine, sulfate
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
The active substance is protamine sulfate, which is used as an anti-heparin, to block the action of heparin and low molecular weight heparins, and to reduce the effect of these substances in the body.
Heparins are used to prevent blood clotting and can cause bleeding.
You may be treated with this medicine:
Do not use Protamine sulfate LEO Pharma:
if you are allergic to protamine sulfate or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Consult your doctor, pharmacist or nurse before starting to use this medicine
If you have already been given your injection, tell the healthcare staff if you are in any of the above situations. If you are not sure, discuss it with your doctor.
Children and adolescents
This medicine is not intended for use in children and adolescents.
Other medicines and Protamine sulfate LEO Pharma
Tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines.
Pregnancy and breastfeeding
Pregnancy
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor, nurse or pharmacist for advice before using this medicine.
There is no available information on the use of this medicine in pregnant women.
Protamine sulfate LEO Pharma should not be used during pregnancy unless clearly necessary.
Breastfeeding
If you are breastfeeding, ask your doctor, nurse or pharmacist for advice before using this medicine.
There is no available information on the use of this medicine in breastfeeding women.
Breastfeeding should be discontinued if treatment with Protamine sulfate LEO Pharma is necessary.
Driving and using machines
The influence of this medicine on the ability to drive and use machines is negligible.
Protamine sulfate LEO Pharma contains sodium
This medicine contains less than 1 mmol (23 mg) of sodium per 5 ml; this is essentially "sodium-free".
Your doctor will decide the amount of Protamine sulfate LEO Pharma suitable for you. This depends on the results of blood tests to determine how much heparin needs to be neutralized.
Protamine sulfate LEO Pharma is for intravenous administration and can be administered as a slow injection (over about 10 minutes) into a vein or can be added to the solution in your "drip".
You may need additional doses, especially if you need to reverse a low molecular weight heparin or if your surgery is long.
No more than 5 ml of this medicine will be administered to you in each 10-minute treatment period.
If you have been given too much Protamine sulfate LEO Pharma
This can interfere with blood clotting processes, increasing the time it takes for blood to clot.
In case of overdose or accidental administration, consult the Toxicology Information Service. Phone 91 562 04 20, or go to the emergency department of the nearest hospital, accompanied by this leaflet.
If you have any other questions about the use of this product, ask your doctor, nurse or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects:
If you experience any of the following side effects, you should contact your doctor, nurse or local hospital immediately for emergency help:
The following less serious side effects have been observed with the administration of Protamine sulfate LEO Pharma:
Reporting of side effects
If you experience any side effects, ask your doctor, pharmacist or nurse, even if they are not listed in this leaflet. You can also report them to the Spanish Medicines and Healthcare Products Agency (AEMPS) at www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Protamine sulfate LEO Pharma
Appearance of Protamine sulfate LEO Pharma and contents of the pack
This product is presented as an injectable and infusion solution, being a colorless and clear liquid.
Ampoules of 5 ml. Pack sizes of 5 or 50 ampoules.
Not all pack sizes may be marketed.
Marketing authorisation holder and manufacturer
Marketing authorisation holder
LEO Pharma A/S
55 Industriparken, DK-2750 Ballerup, Denmark.
Manufacturer
CENEXI SAS
52, rue Marcel et Jacques Gaucher, 94120 Fontenay-sous-Bois, France.
You can ask for more information about this medicine by contacting the local representative of the marketing authorisation holder:
Laboratorios LEO Pharma, S.A.
Via Laietana 33, 7th floor
08003 Barcelona
Spain
Date of last revision of this leaflet: 09/2014
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) (http://www.aemps.gob.es/).
<------------------------------------------------------------------------------------------------------>
Please cut along this line and keep this part of the leaflet. Give the rest of the leaflet to the patient.
This information is intended only for healthcare professionals:
Protamine sulfate LEO Pharma 1,400 UI anti-heparin (10 mg)/ml injectable and infusion solution
1 ml contains 1,400 UI anti-heparin protamine sulfate (equivalent to 10 mg)
5 ml contain 7,000 UI anti-heparin protamine sulfate (equivalent to 50 mg)
For more information, see the full summary of product characteristics.
Therapeutic indications:This medicine may be used to neutralize the anticoagulant effect of heparin or low molecular weight heparin (see summary of product characteristics).
Posology and method of administration
This medicine is administered as a slow intravenous injection over a period of about 10 minutes or as a slow intravenous infusion. The maximum dose to be administered as a single injection (bolus dose) should not exceed 5 ml (7,000 UI anti-heparin/50 mg). The dose is usually determined based on the results of blood coagulation tests. For this purpose, the determination of activated partial thromboplastin time (APTT), activated clotting time (ACT), anti-Xa activity and protamine neutralization test are suitable. Coagulation tests are usually performed 5-15 minutes after administration of protamine sulfate. Additional doses may be necessary since protamine sulfate is eliminated from the blood more rapidly than heparin and especially more rapidly than low molecular weight heparin. Prolonged absorption after subcutaneous administration of heparin or low molecular weight heparin may also indicate that repeated doses should be administered.
Neutralization of Heparin
1 ml of Protamine sulfate LEO Pharma (10 mg of protamine sulfate) will neutralize approximately 1,400 UI of heparin. Since heparin has a relatively short half-life when administered intravenously (30 minutes - 2 hours), the dose of protamine sulfate should be adjusted based on the time elapsed since the discontinuation of intravenous heparin administration. The dose of protamine sulfate in relation to the amount administered of heparin should be reduced if more than 15 minutes have elapsed since the end of the intravenous heparin injection.
Neutralization of Low Molecular Weight Heparin (LMWH)
Generally, a dose of 1 ml of Protamine sulfate LEO Pharma (10 mg of protamine sulfate) is recommended for every 1,000 UI anti-Xa of LMWH. Protamine sulfate neutralizes different LMWHs to varying degrees; therefore, in case of overdose, the manufacturer's recommendations for the specific LMWH should be consulted. Protamine sulfate is only capable of partially neutralizing the anti-Xa activity of LMWH, and neutralization will not be more effective if higher doses of protamine sulfate are administered than recommended. There is a risk that neutralization may be incomplete with a single injection of protamine sulfate in the case of neutralization of subcutaneously administered LMWH. The absorption phase from the injection site will result in additional amounts of LMWH reaching the circulation (also called 'depot effect'). In these cases, repeated administrations of protamine sulfate or a continuous slow intravenous infusion may be necessary. When estimating the dose of protamine sulfate required in relation to the time elapsed since the administration of the last dose of LMWH, the half-life of LMWHs should also be taken into account.
Cardiopulmonary bypass procedures
The dose of protamine sulfate should be determined based on the results of blood coagulation tests. For this purpose, the determination of activated partial thromboplastin time (APTT), activated clotting time (ACT), anti-Xa activity and protamine neutralization test are suitable. Coagulation tests are usually performed 5-15 minutes after administration of protamine sulfate. Generally, a dose of 0.1 ml to 0.2 ml (1-2 mg) of Protamine sulfate LEO Pharma is administered intravenously for every 100 units of heparin administered.
Special precautions for disposal
Use immediately after opening the ampoule.
Discard the remaining solution.
Use only if the solution is clear, without visible particles, and the ampoule is intact. Disposal of unused medicine and all materials that have come into contact with it should be done in accordance with local regulations.
Protamine sulfate LEO Pharma can be administered as a slow intravenous infusion, in which case it should be used with a sodium chloride 9 mg/ml solution. Such mixtures should not be stored.